Medicus Pharma (MDCXW) Long-Term Debt Issuances (2024 - 2025)
Medicus Pharma (MDCXW) reported Long-Term Debt Issuances of $11.9 million for Q4 2025, up 329.41% on a YoY basis from $2.8 million in Q4 2024, and up 363.7% quarter-over-quarter from -$4.5 million in Q3 2025.
Medicus Pharma (MDCXW) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends
Medicus Pharma has reported Long-Term Debt Issuances for 2 years, with the latest figure at $11.9 million in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Debt Issuances rose 329.41% year-over-year to $11.9 million; the trailing twelve-month figure through Dec 2025 stood at $2.2 million (changed N/A YoY), and the FY2025 full-year result was $11.9 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2025 stood at $11.9 million, up from -$4.5 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $11.9 million in Q4 2025, with the low at -$5.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 7.99 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 3.96 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Medicus Pharma | - | - | - | 11.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.87 Mn |
| Dec 31, 2025 | 11.87 Mn |
| Sep 30, 2025 | -4.50 Mn |
| Sep 30, 2025 | -4.50 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | 5.17 Mn |
| Sep 30, 2024 | 5.17 Mn |